'Trk'-ish math: Loxo series B garners $24M for new cancer target
By Randy Osborne
Wednesday, May 7, 2014
With $24 million of series B cash in hand, Loxo Oncology Inc. disclosed more about the pipeline's lead compound in a cancer effort than the company was willing when it garnered $33 million in the series A round last October.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.